ABCC2 and metabolic dysfunction-associated steatohepatitis: Another study with[99mTc]mebrofenin found in patients with nonalcoholic steatohepatitis (NASH)an increase in the systemic and the hepatic exposure of [99mTc]mebrofenin ascompared with healthy subjects due to a decrease in biliary clearance, suggesting thathepatic MRP2 activity is impaired in NASH [112].